JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB196645

HRP Anti-MIF antibody [EPR12463]

Be the first to review this product! Submit a review

|

(1 Publication)

Rabbit Recombinant Monoclonal MIF antibody - conjugated to HRP. Suitable for WB and reacts with Human, Mouse, Rat samples. Cited in 1 publication.

View Alternative Names

GLIF, MMIF, MIF, Macrophage migration inhibitory factor, Glycosylation-inhibiting factor, L-dopachrome isomerase, L-dopachrome tautomerase, Phenylpyruvate tautomerase, GIF

2 Images
Western blot - HRP Anti-MIF antibody [EPR12463] (AB196645)
  • WB

Lab

Western blot - HRP Anti-MIF antibody [EPR12463] (AB196645)

This blot was produced using a 4-12% Bis-tris gel under the MES buffer system. The gel was run at 200V for 35 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 3% milk before being incubated with ab196645 overnight at 4°C. Antibody binding was visualised using ECL development solution ab133406.

All lanes:

Western blot - HRP Anti-MIF antibody [EPR12463] (ab196645) at 1/2000 dilution

Lane 1:

Y79 (Human retinoblastoma cell line) Whole Cell Lysate at 10 µg

Lane 2:

Brain (Human) Tissue Lysate - fetal normal tissue (<a href='/en-us/products/unavailable/brain-human-tissue-lysate-fetal-normal-tissue-ab29467'>ab29467</a>) at 10 µg

Predicted band size: 12 kDa

Observed band size: 12 kDa

true

Exposure time: 4min

Western blot - HRP Anti-MIF antibody [EPR12463] (AB196645)
  • WB

Lab

Western blot - HRP Anti-MIF antibody [EPR12463] (AB196645)

ab196645 was shown to recognize MIF (Macrophage migration inhibitory factor) in wild-type HAP1 cells as signal was lost at the expected MW in MIF knockout cells. Additional cross-reactive bands were observed in the wild-type and knockout cells. Wild-type and MIF knockout samples were subjected to SDS-PAGE. ab196645 and ab8245 (Mouse anti-GAPDH loading control) were incubated overnight at 4°C at 2 μg/ml and 1/20000 dilution respectively. The loading control was imaged using the Licor Odyssey CLx prior to blots being developed with ECL technique.

All lanes:

Western blot - HRP Anti-MIF antibody [EPR12463] (ab196645) at 2 µg/mL

Lane 1:

Wild-type HAP1 whole cell lysate at 20 µg

Lane 2:

MIF knockout HAP1 whole cell lysate at 20 µg

Predicted band size: 12 kDa

Observed band size: 12 kDa

false

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

EPR12463

Isotype

IgG

Conjugation

HRP

Excitation/Emission
Carrier free

No

Reacts with

Human

Applications

WB

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "<p></p>", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/2000", "WB-species-notes": "<p></p>" }, "Mouse": { "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "", "WB-species-checked": "guaranteed", "WB-species-dilution-info": "", "WB-species-notes": "<p></p>" }, "Rat": { "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "", "WB-species-checked": "guaranteed", "WB-species-dilution-info": "", "WB-species-notes": "<p></p>" } } }

Product details

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
pH: 7.4 Preservative: 0.1% Proclin 300 Solution Constituents: PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle|Store in the dark

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Macrophage migration inhibitory factor (MIF) also known as glycosylation-inhibiting factor is a protein with a molecular mass of approximately 12.5 kDa. It plays a mechanistic role as a cytokine that regulates immune responses specifically influencing macrophage behavior. MIF expresses in various cell types including immune and epithelial cells. It gets secreted by activated lymphocytes and macrophages pointing to its involvement in the inflammatory process.
Biological function summary

MIF acts as an upstream regulator of innate immunity and exerts broad influence on cytokine release. MIF elevates pro-inflammatory cytokines like TNF-alpha and IL-1beta promoting an immune response. It does not typically form part of a complex but interacts with cell surface receptors like CD74 triggering intracellular signaling pathways. These interactions illustrate MIF as a regulator of immune cell recruitment and activation.

Pathways

MIF participates in the glucocorticoid receptor regulatory pathway and MAP kinase pathway. It shows interaction with JNK and ERK1/2 proteins which further map into important cellular reactions like stress response and cell proliferation. By integrating into these pathways MIF influences cell survival proliferation and inflammatory cascades emphasizing its role in immune regulation.

MIF links to inflammatory diseases such as rheumatoid arthritis and sepsis. It influences disease progression by interacting with proteins like TNF-alpha and IL-6 contributing to inflammatory damage. Elevated MIF levels often correlate with disease severity in rheumatoid arthritis acting as a potential target for therapy. Furthermore sepsis demonstrates a similar pattern where MIF modulation can impact patient outcomes underlining its relevance in clinical investigations.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Pro-inflammatory cytokine involved in the innate immune response to bacterial pathogens (PubMed : 15908412, PubMed : 17443469, PubMed : 23776208). The expression of MIF at sites of inflammation suggests a role as mediator in regulating the function of macrophages in host defense (PubMed : 15908412, PubMed : 17443469, PubMed : 23776208). Counteracts the anti-inflammatory activity of glucocorticoids (PubMed : 15908412, PubMed : 17443469, PubMed : 23776208). Has phenylpyruvate tautomerase and dopachrome tautomerase activity (in vitro), but the physiological substrate is not known (PubMed : 11439086, PubMed : 17526494). It is not clear whether the tautomerase activity has any physiological relevance, and whether it is important for cytokine activity (PubMed : 11439086, PubMed : 17526494).
See full target information MIF

Publications (1)

Recent publications for all applications. Explore the full list and refine your search

PloS one 15:e0231655 PubMed32325480

2020

Immune complex disease in a chronic monkey study with a humanised, therapeutic antibody against CCL20 is associated with complement-containing drug aggregates.

Applications

Unspecified application

Species

Unspecified reactive species

Susan B Laffan,Andrew S Thomson,Shing Mai,Cindy Fishman,Takahito Kambara,Kiran Nistala,James T Raymond,Shugui Chen,Thulasi Ramani,Laura Pageon,Rodd Polsky,Mark Watkins,Gemma Ottolangui,John R White,Curtis Maier,Michael Herdman,Gerben Bouma
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com